Khurram Khan, MD
Interventional Pain Medicine · Marshall, MINPI 1417164062
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Boston Scientific at 34.9% of the total. Reporting peaked in 2024 at $5,702 and has fallen 99.4% since, to $34 in 2025.
Across 210 payments — averaging $53.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Vertos Medical, Inc.$1K
- Nalu Medical, Inc.$1K
- Genesys Orthopedics Systems, L.L.C.$1K
- Spinefrontier, Inc.$534
- Pacira Therapeutics, Inc.$520
- plus $2K from 19 others
Across 18 payments — averaging $20,264 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nalu Medical, Inc.$231K
- Globus Medical$134K
- Saluda Medical Americas, Inc.$16
What the payments were for
- Travel & lodging$5,35448%
- Food & beverage$5,85452%
- Education$390%
- Gifts$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 25 | $3,925 |
| Vertos Medical, Inc. | 13 | $1,373 |
| Nalu Medical, Inc. | 23 | $1,305 |
| Genesys Orthopedics Systems, L.L.C. | 5 | $1,197 |
| Spinefrontier, Inc. | 3 | $534 |
| Pacira Therapeutics, Inc. | 23 | $520 |
| Abbott | 19 | $477 |
| Stimwave Technologies Incorporated | 5 | $407 |
| Supernus Pharmaceuticals, Inc. | 37 | $378 |
| Amgen(2 entities) | 32 | $212 |
| Nevro Corp. | 3 | $174 |
| SPR Therapeutics, Inc | 2 | $152 |
| Curonix LLC | 2 | $136 |
| Avanos Medical | 2 | $80 |
| Stryker | 2 | $67 |
| Medtronic | 3 | $65 |
| Brixton Biosciences, Inc. | 1 | $48 |
| Orthogenrx Inc. | 2 | $36 |
| Tersera Therapeutics LLC | 2 | $35 |
| Globus Medical | 1 | $34 |
| Painteq LLC | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Boehringer Ingelheim | 1 | $22 |
| AbbVie | 1 | $16 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SACROILIAC JOINT FUSION SYSTEM$2,199
- Superion Indirect Decompression System$1,300
- mild Device Kit$988
- SPECTRA WAVEWRITER$929
- Nalu Neurostimulation System$759
- InSpan$436
- SacroFuse$436
- NanoFuse Putty$436
- Intracept$299
- StimQ Receiver Stimulator Kit Channel A US w Receiver$298
- StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver$298
- StimQ Freedom 8A Receiver Kit Channel A US w Receiver$298
- Freedom 4A Receiver Kit Channel A US w Receiver$298
- Freedom 8A Receiver Kit Channel A US w Receiver$298
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$123
- Senza$110
- PROCLAIM$109
How this compares
$11,262 in reported general payments places this provider in the 85th percentile of 88 interventional pain medicine providers in Michigan.
See all interventional pain medicine providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $44,392 |
| MyrbetriqMirabegron | 39 | $12,896 |
| JardianceEmpagliflozin | 15 | $9,195 |
| EntrestoSacubitril/Valsartan | 15 | $8,801 |
| Buprenorphine | 52 | $8,617 |
| BrilintaTicagrelor | 18 | $8,589 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,309 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,286 |
| Pregabalin | 361 | $6,401 |
| Enoxaparin Sodium | 12 | $4,861 |
| Tizanidine Hcl | 263 | $2,421 |
| Hydrocortisone | 14 | $2,340 |
| Gabapentin | 184 | $2,270 |
| Atorvastatin Calcium | 140 | $2,174 |
| Levothyroxine Sodium | 221 | $2,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $22 | $9,19515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 88 interventional pain medicine providers in Michigan.
Other interventional pain medicine in Marshall
- Ryan PollinaSaint Clair Shores$144K
- Ariel MajjhooMonroe$124K
- Chad BrummettAnn Arbor$109K
- Anand ThakurClinton Township$102K
- Evan PeskinFlint$72K
- Richard FerroLansing$31K
- John ChatasAnn Arbor$29K
- Bryant IttiaraAllen Park$28K
- Fadi DellyWyandotte$25K
- Vincent RampersaudFlint$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.